Vivos Therapeutics reported revenue of $5.15M and net income of -$5.52M for the quarter ended Jun 2026, up 34.9% year over year. This income statement covers 27 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||||
| Revenue | 4.55M | 4.39M | 3.64M | 4.18M | 4.25M | 3.95M | 3.86M | 3.40M | 3.30M | 3.25M | 3.42M | 4.05M | 3.86M | 3.70M | 3.02M | 3.82M | 6.78M | 3.82M | 5.14M | 5.15M | |||||||
| Cost of RevenueCost of Rev | 1.36M | 1.29M | 1.09M | 1.60M | 1.75M | 1.57M | 1.52M | 1.30M | 1.55M | 1.16M | 1.48M | 1.40M | 1.53M | 1.60M | 1.51M | 1.71M | 2.85M | 0.84M | 2.08M | 2.20M | |||||||
| Gross Profit | 3.18M | 3.11M | 2.55M | 2.59M | 2.50M | 2.38M | 2.34M | 2.10M | 1.75M | 2.09M | 1.94M | 2.65M | 2.33M | 2.10M | 1.51M | 2.11M | 3.94M | 2.99M | 3.06M | 2.95M | |||||||
| Operating items | |||||||||||||||||||||||||||
| Depreciation & Amortization - TotalDep. & Amort. (Tot) | 0.10M | 0.10M | 0.20M | 0.20M | 0.20M | 0.30M | 0.20M | 0.10M | 0.10M | 0.20M | 0.10M | 0.10M | 0.10M | 0.10M | 0.20M | 0.30M | 0.40M | -0.20M | 0.30M | 0.30M | |||||||
| Research & DevelopmentR&D | 1.98M | 1.32M | 0.75M | 1.70M | 1.11M | 1.35M | 0.63M | 0.59M | 0.64M | 0.61M | 0.66M | 0.32M | 0.35M | 0.41M | 0.36M | 0.26M | 0.40M | 0.38M | 0.25M | 0.15M | |||||||
| Selling, General & AdministrativeSG&A | 6.52M | 8.12M | 8.28M | 7.69M | 6.62M | 6.92M | 6.54M | 5.88M | 4.60M | 5.47M | 4.92M | 4.12M | 4.49M | 4.35M | 4.89M | 6.41M | 7.88M | 8.55M | 8.97M | 7.11M | |||||||
| Other Operating ExpensesOther Opex | 0.09M | 0.98M | -0.04M | -0.04M | -0.03M | -0.13M | -0.03M | 0.05M | 0.05M | -0.05M | 0.05M | 0.04M | 0.05M | 0.04M | -0.02M | 0.01M | -0.02M | 0.64M | 0.15M | 0.21M | |||||||
| Operating ExpensesOpex | 8.69M | 10.52M | 9.19M | 9.55M | 7.90M | 8.45M | 7.34M | 6.62M | 5.39M | 6.22M | 5.72M | 4.59M | 4.98M | 4.90M | 5.43M | 6.97M | 8.67M | 9.37M | 9.67M | 7.78M | |||||||
| Operating IncomeOp. Inc | -5.50M | -7.41M | -6.64M | -6.96M | -5.41M | -6.06M | -5.00M | -4.52M | -3.64M | -4.13M | -3.79M | -1.94M | -2.65M | -2.81M | -3.92M | -4.87M | -4.73M | -6.38M | -6.62M | -4.83M | |||||||
| EBIT | -5.50M | -7.41M | -6.64M | -6.96M | -5.41M | -6.06M | -5.00M | -4.52M | -3.64M | -4.13M | -3.79M | -1.94M | -2.65M | -2.81M | -3.92M | -4.87M | -4.73M | -6.38M | -6.62M | -4.83M | |||||||
| Non-operating items | |||||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.01M | 0.00M | 0.04M | 0.04M | 0.04M | ||||||||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.06M | -0.10M | -0.04M | -0.04M | -0.04M | -0.04M | 0.05M | -0.23M | -0.05M | -0.01M | -0.00M | -0.02M | -0.02M | -0.07M | -0.00M | -0.16M | -0.68M | -0.63M | -1.17M | -1.05M | |||||||
| Net income details | |||||||||||||||||||||||||||
| EBT | -5.45M | -7.41M | -5.33M | -6.99M | -5.43M | -6.19M | -1.70M | -5.53M | -2.09M | -4.30M | -3.76M | -1.93M | -2.62M | -2.88M | -3.86M | -5.01M | -5.40M | -6.95M | -7.75M | -5.52M | |||||||
| Profit After TaxPAT | -5.45M | -7.39M | -5.33M | -6.99M | -5.43M | -6.04M | -1.70M | -5.53M | -2.09M | -4.28M | -3.76M | -1.93M | -2.88M | -3.38M | -3.86M | -5.01M | -5.47M | -5.78M | -7.75M | -5.52M | |||||||
| Income from Non-Controlling InterestsInc. Minority | -0.07M | -0.04M | |||||||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -5.45M | -7.41M | -5.33M | -6.99M | -5.43M | -6.19M | -1.70M | -5.53M | -2.09M | -4.30M | -3.76M | -1.93M | -2.62M | -2.88M | -3.86M | -5.01M | -5.40M | -6.95M | -7.75M | -5.52M | |||||||
| Consolidated Net IncomeConsol Net Inc. | -5.45M | -7.41M | -5.33M | -6.99M | -5.43M | -6.19M | -1.70M | -5.53M | -2.09M | -4.30M | -3.76M | -1.93M | -2.62M | -2.88M | -3.86M | -5.01M | -5.40M | -6.95M | -7.75M | -5.52M | |||||||
| Income towards Parent CompanyParent Net Inc | -5.45M | -7.41M | -5.33M | -6.99M | -5.43M | -6.19M | -1.70M | -5.53M | -2.09M | -4.30M | -3.76M | -1.93M | -2.62M | -2.88M | -3.86M | -5.01M | -5.40M | -6.95M | -7.75M | -5.52M | |||||||
| Preferred Dividend PaymentsPref Dividends | |||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -5.45M | -7.39M | -5.33M | -6.99M | -5.43M | -6.09M | -1.70M | -5.53M | -2.09M | -4.30M | -3.76M | -1.93M | -2.62M | -2.88M | -3.86M | -5.01M | -5.40M | -6.95M | -7.68M | -5.48M | |||||||
| Additional items | |||||||||||||||||||||||||||
| EPS (Basic) | -6.55 | -8.70 | -6.28 | -8.23 | -6.40 | -6.61 | -1.72 | -4.62 | -1.75 | -3.53 | -1.63 | -0.60 | -0.40 | -0.57 | -0.45 | -0.55 | -0.49 | -0.68 | -0.52 | -0.31 | |||||||
| EPS (Diluted) | -8.23 | -6.40 | -6.61 | -1.72 | -4.62 | -1.75 | -3.53 | -1.63 | -0.60 | -0.40 | -0.57 | -0.45 | -0.55 | -0.49 | -0.68 | -0.52 | -0.31 | ||||||||||
| Shares Outstanding | 0.83M | 0.85M | 0.85M | 0.85M | 0.85M | 0.92M | 0.99M | 1.20M | 1.20M | 1.22M | 2.31M | 3.23M | 6.62M | 5.02M | 8.60M | 9.09M | 10.96M | 10.27M | 14.63M | 17.68M | |||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.85M | 0.85M | 0.92M | 0.99M | 1.20M | 1.20M | 1.22M | 2.31M | 3.23M | 6.62M | 5.02M | 8.60M | 9.09M | 10.96M | 10.27M | 14.63M | 17.68M | ||||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.92M | 0.92M | 0.92M | 0.92M | 0.92M | 0.92M | 0.99M | 1.20M | 1.20M | 1.22M | 2.73M | 3.40M | 6.62M | 5.89M | 8.60M | 7.32M | 10.96M | 9.29M | 13.49M | 14.53M | |||||||
| EBITDA | -5.40M | -7.31M | -6.44M | -6.76M | -5.21M | -5.76M | -4.80M | -4.42M | -3.54M | -3.93M | -3.69M | -1.84M | -2.54M | -2.71M | -3.72M | -4.57M | -4.33M | -6.58M | -6.32M | -4.53M | |||||||
| Interest ExpensesInt Expense | 0.01M | 0.00M | 0.04M | 0.04M | 0.04M |